CubicFarms Announces Feed as a Service MOT with Van Der Kooi Dairy in Riverdale, California

Aug 04, 2023

VANCOUVER, BC - CubicFarm® Systems Corp. ("CubicFarms" or the "Company") (TSX: CUB), a leading local chain agricultural technology company, announced that its ruminant livestock feed subsidiary company, HydroGreen Inc. ("HydroGreen"), has signed a Memorandum of Terms ("MOT") with Daniel Van Der Kooi, owner of Van Der Kooi Dairy, which is a large dairy farm based in Riverdale, California. Van Der Kooi has signed on to purchase 10,000 tons of sprouted-grain feed per year from HydroGreen's future feed facility in Riverdale, California.

Feed from the planned first building at the future Riverdale facility has been committed, so Van Der Kooi Dairy will purchase feed from a second building that will house 10 additional HydroGreen GLS 808 commercial-scale machines. A system of 10 GLS 808 machines can produce up to 34 tons of feed per day, which amounts to approximately 12,000 tons of feed per building annually. Therefore, Van Der Kooi's purchase of 10,000 tons per year represents most of the capacity of that second building.

This project not only serves to validate HydroGreen's in-field product, but it also presents an opportunity to expand its sales to other dairy and beef operations in the region. Furthermore, the undertaking aims to demonstrate the viability of HydroGreen's innovative Feed as a Service ("FaaS") business model and facilitate accelerated product adoption.

FaaS is an innovative agricultural model where HydroGreen will operate a regional feed facility and harvest the sprouted-grain nutrition from HydroGreen machines to sell to livestock feeding operations in the area. Having HydroGreen run operations at the feed facilities guarantees optimal feed production, quality control, and enhanced animal performance outcomes for producers.

Source : Newswire.ca

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.